Journal
REPRODUCTIVE TOXICOLOGY
Volume 20, Issue 1, Pages 175-178Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.reprotox.2004.12.001
Keywords
levetiracetam; antiepileptic drugs; epilepsy; pregnancy; malformation; birth defect; birth weight; fetal exposure
Categories
Ask authors/readers for more resources
Prenatal exposure to levetiracetam (LEV) has been shown to cause skeletal abnormalities and growth retardation in animal studies, but the teratogenicity of this new antiepileptic drug in humans is still unknown. We detected no malformations in a series of I I pregnancies with LEV exposure, although it was striking that three cases had a low birth weight. There may be an association between maternal LEV use and reduced birth weight. but too few cases have been monitored so far. We recommend that the outcomes of all pregnancies exposed to LEV should be carefully registered. (c) 2004 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available